Search
for
Sort by
Research 30 of 145
- Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
- A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
- A Disease-Modifying Approach for Advanced Hidradenitis Suppurativa (Regimen with Metformin, Liraglutide, Dapsone, and Finasteride): A Case Report
- Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
- EFFECTS OF LIRAGLUTIDE ON VISCERAL ADIPOSITY INDEX IN WOMAN OF REPRODUCTIVE AGE WITH PREDIABETES
- Combination of metformin with liraglutide in treating HAIR-AN syndrome in children: A case report and literature review.
- Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing
- GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
- Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review
- Hormonal Treatments in Hidradenitis Suppurativa: A Systematic Review
- Targeting Obesity in PCOS: A Review of Current Pharmacological Interventions and Future Directions
- Caring for women with polycystic ovary syndrome
- 0439 Temporal–phenotype signatures of alopecia associated with GLP-1–based therapies: A PRISMA-ScR scoping review
- 76708 Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization
- Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions—A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
- Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends
- Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
- Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
- Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
- The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
- Effect of High Levels of Testosterone on Cardiovascular Risk in Polycystic Ovary Syndrome (PCOS)
- A Systematic Review of the Cutaneous Adverse Effects of GLP-1 Agonists
- The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
- Exploring the Role of GLP‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review
- Hepatotoxicity Secondary to A Drug to Lose Weight, "Orlistat": to take into Account as a Differential Diagnosis
- Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
- Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
- Polycystic ovary syndrome: Pathophysiology, Symptoms, Risk factors, and Pharmacological treatment